*001342025
*00520241126023527.0
*007ta
*008200131s2020    no a   e m    00  0 eng
*00901826nam a2200361 c 4500
*019  $bl
*020  $a978-82-8377-583-9$qheftet
*035  $a(EXLNZ-47BIBSYS_NETWORK)999921001389402201
*035  $a(NO-LaBS)13360138(bibid)
*040  $aNO-OsNB$bnob$erda
*060 4$aWJ 762
*1001 $aBraadland, Peder Rustøen$d1988-$0(NO-TrBIB)1581514959471$4aut$_62107900
*24510$aTargeting therapy resistance in advanced prostate cancer$cPeder Rustøen Braadland
*264 1$a[Oslo]$bInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo$c2020
*300  $a1 bind (varierende paginering)$billustrasjoner$c24 cm
*336  $atekst$0http://rdaregistry.info/termList/RDAContentType/1020$2rdaco
*337  $auformidlet$0http://rdaregistry.info/termList/RDAMediaType/1007$2rdamt
*338  $abind$0http://rdaregistry.info/termList/RDACarrierType/1049$2rdact
*4901 $aSeries of dissertations submitted to the Faculty of Medicine, University of Oslo
*500  $aDelvis opptrykk av artikler
*502  $aAvhandling (ph.d.) - Universitetet i Oslo, 2020
*533  $aElektronisk reproduksjon$b[Norge]$cNasjonalbiblioteket Digital$d2024-11-25
*650 2$aAdenocarcinoma$0(DNLM)D000230$_62108000
*650 2$aAndrogen Antagonists$0(DNLM)D000726$_62108100
*650 2$aProstatic Neoplasms, Castration-Resistant$0(DNLM)D064129$_62108200
*650 2$aReceptors, Adrenergic, beta-2$0(DNLM)D018343$_62108300
*7102 $aUniversitetet i Oslo$bDet medisinske fakultet$0(NO-TrBIB)90302138$4pbl$_10213300
*7102 $aUniversitetet i Oslo$bInstitutt for klinisk medisin$0(NO-TrBIB)15000758$4dgg$_10213400
*830 0$aSeries of dissertations submitted to the Faculty of Medicine, University of Oslo$_10213500
*85641$3Fulltekst$uhttps://urn.nb.no/URN:NBN:no-nb_digibok_2024110648152$yNettbiblioteket$zDigital representasjon
*913  $aNorbok$bNB
*917  $ad
*999  $aoai:nb.bibsys.no:999920041979102202$b2021-11-14T20:12:53Z$z999920041979102202
^